Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Canagliflozin on Renal Endpoints in Adults With Type 2 Diabetes Mellitus
2013-003050-25Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Canagliflozin with Placebo (2 arms). Primary endpoint: Progression of albuminuria. Started Nov 2013; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2013-003050-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003050-25.